Form 4 for NYAX Nayax Ltd.
Accepted 2026-05-18 07:59:20 ET · period of report 2026-05-15 · accession 0001976408-26-000440 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-18 07:59 | 2026-05-15 | NYAX | Sever Michal | CMO | M - OptEx | $21.35 | +5,000 | 20.7K | +32% | +$106.8K |
| DM | 2026-05-18 07:59 | 2026-05-15 | NYAX | Sever Michal | CMO | S - Sale+OE | $64.32 | -5,000 | 17.3K | -22% | -$321.6K |
| DM | 2026-05-18 07:59 | 2026-05-15 | NYAX | Sever Michal | CMO | M - OptEx | $0.00 | -5,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-05-15 | M | A | 1,563 | $21.35 | 18,869 | D | — | — | (F1) The shares were acquired upon the exercise of stock options (F2) The exercise price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the grant date. |
| 2 | Common | Ordinary Shares | 2026-05-15 | S | D | 1,563 | $64.41 | 17,306 | D | — | — | (F3) The shares sold were acquired upon the exercise of stock options on the same date (F4) The price reported is a weighted average price. The reporting person undertakes to provide full information, regarding the number of shares and prices at which the transaction was effectuated, upon request. The sale price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the Execution date. |
| 3 | Common | Ordinary Shares | 2026-05-15 | M | A | 3,437 | $21.35 | 20,743 | D | — | — | (F1) The shares were acquired upon the exercise of stock options (F2) The exercise price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the grant date. |
| 4 | Common | Ordinary Shares | 2026-05-15 | S | D | 3,437 | $64.28 | 17,306 | D | — | — | (F3) The shares sold were acquired upon the exercise of stock options on the same date (F4) The price reported is a weighted average price. The reporting person undertakes to provide full information, regarding the number of shares and prices at which the transaction was effectuated, upon request. The sale price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the Execution date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-05-15 | M | D | 1,563 | $0.00 | 0 | D | $21.35 · 2025-03-30 to 2027-03-28 | 1,563 Ordinary Shares | (F2) The exercise price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the grant date. (F5) The options reported herein were exercised and the underlying shares were sold on the same date as reported in Table I. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-05-15 | M | D | 3,437 | $0.00 | 0 | D | $21.35 · 2023-03-28 to 2027-03-28 | 3,437 Ordinary Shares | (F2) The exercise price is denominated in New Israeli Shekels. The U.S. dollar amount reported reflects the exchange rate on the grant date. (F5) The options reported herein were exercised and the underlying shares were sold on the same date as reported in Table I. |